Earnings due 23 Mar: SM1.AX Synlait Milk ASX pre-market 21 Mar 2026: margin guide key

We start pre-market with the SM1.AX stock trading at A$0.40, up 12.68% on low volume ahead of earnings due 23 Mar 2026. Investors will focus on margin guidance and infant-nutrition demand after recent volatility. This earnings spotlight looks at near-term catalysts, valuation, and the risks that can move Synlait Milk Limited on the ASX in Australia.

SM1.AX stock pre-market snapshot

SM1.AX stock opened at A$0.36 and is trading at A$0.40 with a daily range A$0.36–A$0.40 and volume 7,089 shares. Market capitalisation is A$241.28M and shares outstanding are 603,198,098. The company reports earnings on 23 Mar 2026, so price action today reflects positioning ahead of that release.

Earnings preview and key drivers for SM1.AX stock

Analysts will watch revenue mix, infant formula volumes and gross margin trends as the core drivers for SM1.AX earnings. Synlait’s revenue per share is A$3.04 and recent gross margins were thin, so modest margin improvement would be material. Management commentary on China demand, supply chain costs, and pricing will likely set the tone for the quarter.

Valuation and financial metrics in SM1.AX analysis

Synlait reports EPS of -A$0.06 and a negative PE of -6.67, reflecting recent losses. Key valuation ratios include P/B 0.37, P/S 0.16, and EV/EBITDA 19.75. Free cash flow per share is A$0.24, giving a free cash flow yield near 49.00% on current price. The current ratio at 0.68 signals working capital pressure to monitor.

Meyka grade and analyst context

Meyka AI rates SM1.AX with a score out of 100: 65.85 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The mixed signals are sturdy cash flow but weak profitability, so the grade reflects neutral conviction. These grades are not guaranteed and are not financial advice.

Technical setup and sector comparison for SM1.AX stock

Technically SM1.AX shows RSI 46.49 and ADX 32.35, indicating trend strength but neutral momentum. The 50-day average is A$0.45 and the 200-day average is A$0.57, so price sits below key moving averages. In the Consumer Defensive sector on the ASX, packagers face margin pressure; sector averages point to stronger ROE than Synlait’s current negative ROE.

Price targets, forecast and key risks

Meyka AI’s near-term price scenarios: conservative A$0.60, base A$0.75, bullish A$1.05, bearish A$0.25. Risks include commodity milk input volatility, slower China demand, and working capital strain. Opportunities are margin recovery from pricing and cost control. Use the earnings release as a catalyst to reassess targets and risk exposure.

Final Thoughts

Key takeaways for SM1.AX stock: Synlait trades at A$0.40 ahead of earnings on 23 Mar 2026, with the market watching margin commentary and infant-nutrition demand. Valuation metrics are mixed: negative EPS (-A$0.06), low P/B (0.37), and strong free cash flow per share (A$0.24). Meyka AI’s forecast model projects A$0.75 over the next year, implying an upside of 86.65% from the current price, but forecasts are model-based projections and not guarantees. Investors should weigh cash flow strength against profitability and working capital risk. For a quick reference, see Synlait’s site and our ASX page and our internal page for real-time updates at Meyka SM1.AX stock page. Meyka AI provides this AI-powered market analysis to help frame outcomes, not to recommend trades.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.